First subjects screened in Aptahem’s FIH study with Apta-1
Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first healthy volunteers have been screened for inclusion in the clinical First in Human (FIH) study with the drug candidate Apta-1.The randomized, placebo-controlled Phase 1 study will evaluate the safety and tolerability of intravenous Apta-1 in healthy volunteers (HV). The first HV subjects have now been screened and are ready for the first dosing later in December. CEO Mikael Lindstam comments: ”It is with great pleasure that